Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes

被引：0
|
作者：
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Palo Alto VA Healthcare, Palo Alto, VA USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
112
引用
收藏
页码：31A / 31A
页数：1
相关论文
共 50 条
  • [41] HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe, Marian Priyanthi
    de Boer, Willem Bastiaan
    Khor, Tze Sheng
    Ooi, Esther M.
    Jene, Nic
    Jayasinghe, Sureshini
    Fox, Stephen B.
    PATHOLOGY, 2014, 46 (03) : 184 - 187
  • [42] Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations
    Lambein, Kathleen
    Praet, Marleen
    Forsyth, Ramses
    Van den Broecke, Rudy
    Braems, Geert
    Matthys, Bart
    Cocquyt, Veronique
    Denys, Hannelore
    Pauwels, Patrick
    Libbrecht, Louis
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (03) : 200 - 207
  • [43] Correlation between HER2/CEP17 ratio and neoadjuvant trastuzumab and pertuzumab pathologic complete response
    Choi, J.
    Jeon, C. W.
    Jung, S. U.
    Kim, A. L.
    Lee, S. A.
    Woo, S. U.
    Suh, Y. J.
    BREAST, 2019, 44 : S74 - S75
  • [44] Relationship between Pathological Features, Her2 Protein Expression, and HER2 and CEP17 Copy Numbers in DCIS.
    Lambein, K.
    Van Bockstal, M.
    Praet, M.
    Denys, H.
    Braems, G.
    Nuyts, A.
    Cocquyt, V.
    Pauweis, P.
    Van Den Broecke, R.
    Libbrecht, L.
    CANCER RESEARCH, 2011, 71
  • [45] CEP17 "Polysomy" (CEP17P): Definition and Impact on HER2 Copy Number (CN) in Breast Carcinoma
    Astvatsaturyan, K.
    Mirocha, J.
    Bose, S.
    MODERN PATHOLOGY, 2012, 25 : 24A - 24A
  • [46] Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features
    Zare, Somaye Y.
    Lin, Leo
    Alghamdi, Abrar G.
    Daehne, Svenja
    Roma, Andres A.
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    HUMAN PATHOLOGY, 2019, 83 : 7 - 13
  • [47] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Dell'Aquila, Marie
    Hasteh, Farnaz
    Fadare, Oluwole
    MODERN PATHOLOGY, 2018, 31 : 117 - 117
  • [48] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number <4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Dell'Aquila, Marie
    Hasteh, Farnaz
    Fadare, Oluwole
    LABORATORY INVESTIGATION, 2018, 98 : 117 - 117
  • [49] A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
    Shuling Zhou
    Hong Lv
    Anqi Li
    Ming Li
    Siyuan Zhong
    Hongfen Lu
    Xiaoyan Zhou
    Qianming Bai
    Wentao Yang
    BMC Cancer, 23
  • [50] Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)
    Greenwell, Kathriena
    Hussain, Lala
    Lee, David
    Bramlage, Matthew
    Bills, Gordon
    Mehta, Apurva
    Jackson, Amie
    Wexelman, Barbara
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (02) : 249 - 254
12345